CDC director announces her resignation from the agency

President Joe Biden today announced that the director of the U.S. Centers for Disease Control and Prevention, Rochelle Walensky, MD, is resigning from her position. 

Walensky was appointed to the role in December 2020 by President Briden. She replaced Robert Redfield, MD, who served as CDC director throughout most of former President Donald Trump’s administration. Walensky first took over as the post in January 2021 during the widespread rollout of COVID vaccinations in the U.S. 

In a public statement, President Biden thanked Walensky for the “honesty and integrity” she brought to the role amid a pivotal time in the pandemic. 

“Dr. Walensky leaves CDC a stronger institution, better positioned to confront health threats and protect Americans. We have all benefited from her service and dedication to public health, and I wish her the best in her next chapter,” Biden said. 

News of the CDC director’s departure comes on the same day as an announcement made by the World Health Organization declaring the end of the COVID global health emergency. Walensky commented on the development in a letter to President Biden, which was also shared with CDC employees. 

“The end of the COVID-19 public health emergency marks a tremendous transition for our country, for public health, and in my tenure as CDC director,” Walensky wrote. “I took on this role, at your request, with the goal of leaving behind the dark days of the pandemic and moving CDC–and public health–forward into a much better and more trusted place.” 

According to an email sent to CDC employees (shared with CNN) on Friday, May 5, Walensky’s last day will be June 30. 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.